Insights

Growing CyPath Revenue CyPath Lung testing has shown revenue growth with approximately $1.1M in CyPath Lung testing revenue for the first nine months of 2026, up 79% year over year, indicating strong demand and a solid upsell opportunity to expand existing customers and add new clinics or labs.

Strategic Partnerships Recent licensing to Precision Pathology Services and new distribution collaboration with AvMedical suggest opportunities to leverage partners for co-selling, broader market access, and faster adoption in clinical laboratories and healthcare networks.

Clinical Impact Positioning CyPath Lung emphasizes noninvasive early detection and risk stratification for pulmonary nodules, which aligns with lung cancer screening programs and CHEST/NAVREF events; selling points include improved diagnostic accuracy, reduced invasive procedures, and potential cost savings for health systems.

Healthcare Market Fit Public engagement at industry events and patient-provider initiatives during National Lung Cancer Awareness Month signals a ready-made channel for outreach to physicians, health systems, and veteran/military populations where NAVREF posters and collaborations can drive pilots and reimbursement discussions.

Financial Growth Signals Strong revenue trajectory with mid-market scale and a solid gross margin around 52% alongside substantial funding indicates capacity for scaled commercial investments, field enablement, and expansion into additional lung disease indications or broader noninvasive diagnostic workflows.

Similar companies to bioAffinity Technologies

bioAffinity Technologies Tech Stack

bioAffinity Technologies uses 8 technology products and services including Microsoft SharePoint, Mailchimp, Microsoft 365, and more. Explore bioAffinity Technologies's tech stack below.

Media & News

bioAffinity Technologies's Email Address Formats

bioAffinity Technologies uses at least 4 email formats:
bioAffinity Technologies Email FormatsExamplePercentage
FL@bioaffinitytech.comJD@bioaffinitytech.com
67%
First.Last@bioaffinitytech.comJohn.Doe@bioaffinitytech.com
22%
FLast@bioaffinitytech.comJDoe@bioaffinitytech.com
9%
Last@bioaffinitytech.comDoe@bioaffinitytech.com
2%

Frequently Asked Questions

What is bioAffinity Technologies's official website and social media links?

Minus sign iconPlus sign icon
bioAffinity Technologies's official website is bioaffinitytech.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does bioAffinity Technologies generate?

Minus sign iconPlus sign icon
As of November 2026, bioAffinity Technologies's annual revenue is estimated to be $1M - $10M.

What is bioAffinity Technologies's SIC code and NAICS code?

Minus sign iconPlus sign icon
bioAffinity Technologies's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does bioAffinity Technologies have currently?

Minus sign iconPlus sign icon
As of November 2026, bioAffinity Technologies has approximately 34 employees across 1 continents, including North America. Key team members include Director: N. M., Pulmonary Sales Executive: D. T. and Sales Specialist: M. T. Explore bioAffinity Technologies's employee directory with LeadIQ.

What industry does bioAffinity Technologies belong to?

Minus sign iconPlus sign icon
bioAffinity Technologies operates in the Biotechnology Research industry.

What technology does bioAffinity Technologies use?

Minus sign iconPlus sign icon
bioAffinity Technologies's tech stack includes Microsoft SharePoint, Mailchimp, Microsoft 365, Google Cloud, Sentry, Wistia, WP Engine and Microsoft Teams.

What is bioAffinity Technologies's email format?

Minus sign iconPlus sign icon
bioAffinity Technologies's email format typically follows the pattern of FL@bioaffinitytech.com. Find more bioAffinity Technologies email formats with LeadIQ.

How much funding has bioAffinity Technologies raised to date?

Minus sign iconPlus sign icon
As of November 2026, bioAffinity Technologies has raised $51M in funding. The last funding round occurred on Aug 13, 2026 for $1.8M.

When was bioAffinity Technologies founded?

Minus sign iconPlus sign icon
bioAffinity Technologies was founded in 2014.
bioAffinity Technologies logo

bioAffinity Technologies

Biotechnology ResearchTexas, United States11-50 Employees

bioAffinity Technologies is a biotechnology research company focused on noninvasive diagnostics for lung disease, including early-stage lung cancer. Its primary product, CyPath Lung, is designed to detect early lung cancer with high sensitivity and specificity, particularly for patients who present with a pulmonary nodule after screening or imaging. The company positions its technology as a means to improve diagnostic accuracy, reduce unnecessary invasive procedures, and lower patient anxiety and medical costs by enabling earlier and more accurate detection.
Based in San Antonio, Texas, bioAffinity Technologies operates in the biotechnology research sector and maintains a growing scientific advisory presence with recent appointments to its Medical and Scientific Advisory Board. The firm has engaged in external collaborations and outreach, including partnerships and presentations at professional gatherings, to advance developments in noninvasive lung diagnostics and related applications.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
11-50

Section iconFunding & Financials

  • $51M

    bioAffinity Technologies has raised a total of $51M of funding over 14 rounds. Their latest funding round was raised on Aug 13, 2026 in the amount of $1.8M as a Post IPO Equity.

  • $1M - $10M

    bioAffinity Technologies's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.